+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ablation Equipments - Medical Devices Pipeline Assessment, 2020

  • ID: 4991934
  • Report
  • February 2020
  • Region: Global
  • 169 Pages
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AngioDynamics Inc
  • Creo Medical Ltd
  • Ethicon US LLC
  • Fractyl Laboratories Inc
  • HistoSonics Inc
  • Mirabilis Medical Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The author's Medical Devices sector report, “Ablation Equipments - Medical Devices Pipeline Assessment, 2020" provides an overview of Ablation Equipments currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Incontinence Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Ablation Equipments under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Ablation Equipments and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Ablation Equipments under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AngioDynamics Inc
  • Creo Medical Ltd
  • Ethicon US LLC
  • Fractyl Laboratories Inc
  • HistoSonics Inc
  • Mirabilis Medical Inc
  • Introduction
  • Ablation Equipments Overview
  • Products under Development
  • Ablation Equipments - Pipeline Products by Stage of Development
  • Ablation Equipments - Pipeline Products by Territory
  • Ablation Equipments - Pipeline Products by Regulatory Path
  • Ablation Equipments - Pipeline Products by Estimated Approval Date
  • Ablation Equipments - Ongoing Clinical Trials
  • Ablation Equipments - Pipeline Products under Development by Companies
  • Ablation Equipments Companies - Pipeline Products by Stage of Development
  • Ablation Equipments - Pipeline Products by Stage of Development
  • Ablation Equipments Companies and Product Overview
  • AngioDynamics Inc Company Overview
  • AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Avenda Health Inc Company Overview
  • Avenda Health Inc Pipeline Products & Ongoing Clinical Trials Overview
  • CPSI Biotech Company Overview
  • CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview
  • Creo Medical Ltd Company Overview
  • Creo Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Deneb Medical SL Company Overview
  • Deneb Medical SL Pipeline Products & Ongoing Clinical Trials Overview
  • Ablation Equipments- Recent Developments
  • Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019
  • Nov 15, 2019: Fractyl announces new data from Revita-1 clinical study showing durable benefits after a single treatment through two years of follow up
  • Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report
  • Nov 08, 2019: Fractyl announces Revita-2 data showing Revita DMR provides statistically significant improvements in blood glucose and liver fat in type 2 diabetes with and without NAFLD
  • Nov 06, 2019: Olympus unveils corporate strategy
  • Appendix
  • Methodology
  • About the Publisher
  • Contact Us
  • Disclaimer

List of Tables
Table 1: Ablation Equipments - Pipeline Products by Stage of Development
Table 2: Ablation Equipments - Pipeline Products by Territory
Table 3: Ablation Equipments - Pipeline Products by Regulatory Path
Table 4: Ablation Equipments - Pipeline Products by Estimated Approval Date
Table 5: Ablation Equipments - Ongoing Clinical Trials
Table 6: Ablation Equipments Companies - Pipeline Products by Stage of Development
Table 7: Ablation Equipments - Pipeline Products by Stage of Development
Table 8: AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Status
Table 10: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Description
Table 11: Nanoknife System - Bladder Cancer - Product Status
Table 12: Nanoknife System - Bladder Cancer - Product Description
Table 13: NanoKnife System - Cervical Cancer - Product Status
Table 14: NanoKnife System - Cervical Cancer - Product Description
Table 15: NanoKnife System - Head And Neck Cancer - Product Status
Table 16: NanoKnife System - Head And Neck Cancer - Product Description
Table 17: NanoKnife System - Lung Cancer - Product Status
Table 18: NanoKnife System - Lung Cancer - Product Description
Table 19: Nanoknife System - Metastatic Lymph Nodes - Product Status
Table 20: Nanoknife System - Metastatic Lymph Nodes - Product Description
Table 21: NanoKnife System - Prostate Cancer - Product Status
Table 22: NanoKnife System - Prostate Cancer - Product Description
Table 23: NanoKnife System - Rectal Cancer - Product Status
Table 24: NanoKnife System - Rectal Cancer - Product Description
Table 25: Nanoknife System - Renal Pelvis Urothelial Neoplasms - Product Status
Table 26: Nanoknife System - Renal Pelvis Urothelial Neoplasms - Product Description
Table 27: NanoKnife System - Stage III Pancreatic Cancer - Product Status
Table 28: NanoKnife System - Stage III Pancreatic Cancer - Product Description
Table 29: Nanoknife System - Stomach Neoplasm - Product Status
Table 30: Nanoknife System - Stomach Neoplasm - Product Description
Table 31: AngioDynamics Inc - Ongoing Clinical Trials Overview
Table 32: NanoKnife System - Prostate Cancer - A Pilot Study in Human Subjects Evaluating the Use of the NanoKnife System for Ablation of Prostate Cancer Tissue in a Low and Intermediate Risk Patient Population
Table 33: NanoKnife System - Prostate Cancer - Efficacy and Safety Assessment of Nanoknife (AngyoDynamics, USA) for Irreversible Electroporation (IRE) of Localized Prostate Cancer
Table 34: NanoKnife System - Prostate Cancer - Examination of Focal Therapies - MR.pdfI-Fusion, HIFU, NanoKnife and Cryotherapy
Table 35: NanoKnife System - Prostate Cancer - Focal Irreversible Electroporation as Salvage Treatment in Radio-recurrent Prostate Cancer: A Prospective Multicenter Pilot Study
Table 36: NanoKnife System - Prostate Cancer - Irreversible Electroporation (IRE) for Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial
Table 37: NanoKnife System - Prostate Cancer - Multi-center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer
Table 38: NanoKnife System - Prostate Cancer - Registry of Irreversible Electroporation for the Ablation of Prostate Cancer with Use of Nanoknife Device; A Multi-center, International Registry to Evaluate the Treatment of Prostate Cancer in Terms of Recurrence, Functional Outcomes and Safety
Table 39: NanoKnife System - Stage III Pancreatic Cancer - A Clinical Research about Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer
Table 40: NanoKnife System - Stage III Pancreatic Cancer - A Pilot Study of Irreversible Electroporation for the Treatment of Upfront Resectable Pancreatic Cancer in the Head of the Pancreas
Table 41: NanoKnife System - Stage III Pancreatic Cancer - A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
Table 42: NanoKnife System - Stage III Pancreatic Cancer - Ablation of Unresectable Locally Advanced Pancreatic Cancer with Nanoknife Irreversible Electroporation (IRE) System: Response and Tolerability
Table 43: NanoKnife System - Stage III Pancreatic Cancer - Assessing Optimal Treatment Settings for the Ablation of Locally Advanced Pancreatic Cancer with CT-guided Percutaneous Irreversible Electroporation (ANTILOPE): A Randomized Feasibility Study
Table 44: NanoKnife System - Stage III Pancreatic Cancer - Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival after Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation: CROSSFIRE Trial
Table 45: NanoKnife System - Stage III Pancreatic Cancer - Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study
Table 46: NanoKnife System - Stage III Pancreatic Cancer - Impact of Irreversible Electroporation on Quality of Life for Patients with Locally Advanced Pancreatic Cancer
Table 47: NanoKnife System - Stage III Pancreatic Cancer - Interest of Irreversible Electroporation in the Treatment of Pancreatic Adenocarcinoma
Table 48: NanoKnife System - Stage III Pancreatic Cancer - IRE: Anti-tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer
Table 49: NanoKnife System - Stage III Pancreatic Cancer - Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial
Table 50: NanoKnife System - Stage III Pancreatic Cancer - Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma
Table 51: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder
Table 52: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers
Table 53: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - A Phase II Clinical Trial: COLDFIRE-2 Study
Table 54: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome
Table 55: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE)
Table 56: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Irreversible Electroporation (IRE) for Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial
Table 57: Nanoknife System - Renal Pelvis Urothelial Neoplasms - Irreversible Electroporation (IRE) for Unresectable Renal Pelvic and Ureteral Neoplasms: Phase I and Phase II Clinical Trial
Table 58: Nanoknife System - Metastatic Lymph Nodes - Irreversible Electroporation (IRE) for Unresectable Lymph Node Metastases: Phase I and Phase II Clinical Trial
Table 59: NanoKnife System - Lung Cancer - Irreversible Electroporation (IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency: Phase I and Phase II Clinical Trial
Table 60: Nanoknife System - Stomach Neoplasm - Irreversible Electroporation (IRE) for Unresectable Stomach Neoplasms: Phase I and Phase II Clinical Trial

List of Figures
Figure 1: Ablation Equipments - Pipeline Products by Stage of Development
Figure 2: Ablation Equipments - Pipeline Products by Territory
Figure 3: Ablation Equipments - Pipeline Products by Regulatory Path
Figure 4: Ablation Equipments - Pipeline Products by Estimated Approval Date
Figure 5: Ablation Equipments - Ongoing Clinical Trials
Note: Product cover images may vary from those shown

Loading
LOADING...

A selection of companies mentioned in this report includes:

  • AngioDynamics Inc
  • Avenda Health Inc
  • CPSI Biotech
  • Creo Medical Ltd
  • Deneb Medical SL
  • Elesta srl
  • Ethicon US LLC
  • Eximo Medical Ltd
  • ExpandoHeat LLC
  • Fractyl Laboratories Inc
  • Harmonic Medical Inc
  • HEPTA Medical SASU
  • HistoSonics Inc
  • Hospital for Special Surgery
  • Integra LifeSciences Holdings Corp
  • Intratherm LLC (Inactive)
  • Massachusetts Institute of Technology
  • Medtronic plc
  • Memorial Sloan Kettering Cancer Center
  • Mirabilis Medical Inc
  • ProstaCare Pty Ltd
  • Pulse Biosciences Inc
  • Sabanci University Nanotechnology Research and Application Center
  • Southern Illinois University Carbondale
  • Thermedical Inc
  • TransEnterix Inc
  • University of California San Francisco
  • University of Texas at Austin
  • University of Wisconsin-Stout
  • Verix Health
Note: Product cover images may vary from those shown